Ukraine-Russia War

Showing 2878 articles
Business

AbCellera Biologics: A Tale of Two Valuations Amid Steep Share Decline

Shares of antibody discovery firm AbCellera Biologics plunged 16.8% last week, reigniting debate over its true worth. While a discounted cash flow model suggests deep undervaluation, its sky-high price-to-sales ratio paints a starkly different picture, leaving investors to navigate conflicting signals in a volatile biotech market.

Business

Fastly's AI-Driven Rally: Sustainable Momentum or Short-Lived Hype?

Fastly's stock has surged on the coattails of broader AI and edge computing optimism, but a closer look reveals a complex picture of short-term gains against longer-term struggles. As the market weighs future growth against persistent losses, investors are left questioning if the recent rally has legs.

Business

Rubrik's Stock Slump Sparks Debate: Is the Cybersecurity Firm Now a Value Play?

Shares of data security company Rubrik have faced significant pressure, declining over 25% in the past month. While the sell-off has pushed its valuation below some fair value estimates, analysts point to stiff competition and cautious IT spending as key headwinds. We examine whether the weakness presents a buying opportunity or a sign of deeper challenges.

Business

From Bitcoin to AI: IREN's Strategic Pivot Gains Momentum as Anthropic's $20B Raise Highlights Infrastructure Demand

Fueled by a landmark $20 billion funding round for AI firm Anthropic, infrastructure provider IREN is seeing its strategic shift from cryptocurrency mining to AI data centers validated by investors. With a key Microsoft partnership and surging capital flows into AI, the company's stock performance reflects a broader market reassessment of its role in high-performance computing.